Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial

Clinical trial NCT05599516 · UNKNOWN

Trial details

NCT number: NCT05599516
Sponsor: National Vaccine and Serum Institute, China
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

COVID-19 Coronavirus Infections

Start date: 2022-11-04
Primary completion: 2023-10-01
Enrollment: 16000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.